Reportlinker Adds South African Pharmaceutical Market Outlook to 2014: Policy Environment, Market Structure, Competitive Landscape, Growth Opportunities

NEW YORK, June 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

South African Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities

http://www.reportlinker.com/p0203702/South-African-Pharmaceutical-Market-Outlook-to-2014-Policy-environment-market-structure-competitive-landscape-growth-opportunities.html

The South African pharmaceutical market was worth over $2bn in 2008. Nearly 75% of pharmaceutical demand in South Africa is met by imports and hence the market value is heavily dependent on currency fluctuations. During 2007-08, the market posted double-digit growth in local currency terms, while declining in US dollar value. Overall sales from the market is expected to pass $3bn in 2012. Factors contributing to growth include the upcoming overhaul of the pharmaceutical regulatory system and healthcare delivery mechanism as well as growth of certain therapy areas in the country.

In general, the replacement of the Medicines Control Council (MCC) with the South African Health Products Regulatory Authority (SAHPRA) and the establishment of a universal healthcare scheme namely the National Health Insurance (NHI) will benefit all companies similarly. The arrival of SAHPRA is being viewed positively by industry organizations as this will lead to expediting drug approvals that translates to faster commercialization and speedier returns on investments. The establishment of a universal healthcare buyer and provider promises increased drug delivery and utilization in the country. However, ramifications in pharmaceutical pricing will threaten margins as bargaining power of a central financier will be significantly higher than the existing fragmented consumer base.

Key features of this report

• Socioeconomic, demographic and epidemiological analysis – Assessment of socioeconomic and demographic features of South Africa. The report also evaluates healthcare delivery parameters in the region.
• Regulatory policy analysis – Insights into the government policy environment relating to pharmaceutical regulation, pricing and reimbursement, and its impact on the industry.
• Sales distribution analysis – Comprehensive analysis of sales distribution in the South African market based on therapeutic classes, brands and companies. The report also analyses the distribution of sales between local players and MNCs operating in the country.
• Market competition/fragmentation analysis – Analysis of market concentration/fragmentation in line with general anti-trust protocols.
• Key events, issues and trends in the South African pharmaceutical market – Impact of key events, issues and trends on the market and Business Insights recommendations to identify resultant opportunities and threats.

Scope of this report

• Quantify disease burden of various communicable and non-communicable pathophysiologic disorders
• Gain a comprehensive understanding of the regulatory, pricing and reimbursement policies and their impact on the industry
• Discover therapy areas with the greatest franchise growth potential and understand the growth drivers.
• Measure the impact of key events, issues and trends in the regulatory landscape, healthcare delivery and therapy areas and be advised with ideas to navigate through the changing environment.
• Forecast sales of all therapy areas through 2014.

Key Market Issues

• Replacement of the MCC by SAHPRA: 2010 will witness the landmark replacement of the MCC with a new authority called the SAHPRA. The SAHPRA is designed to overcome much of the downsides of the MCC. Expedited product approvals and consequent rise in sales is expected.
• The CD4 count criteria for ARV raised from

Non-narcotic analgesics and NSAIDs form the mainstay of pain management 52

Respiratory segment fuelled by demand for asthma/COPD products 53

Rising usage of antidepressants and psycholeptics propel the CNS segment 54

Therapy area forecasts of South Africa, 2009–14 55

Leading brands in South Africa 56

Generic pharmaceutical market in South Africa 57

Therapeutic segmentation of the generics market 61

Leading generics products in South Africa 63

Chapter 4 Competitive landscape 66

Summary 66

Introduction 67

Generics local players and innovation driven MNCs 67

Leading players in South Africa in 2008 71

Market concentration/fragmentation analysis 72

Leading domestic players 72

Aspen 72

Therapeutic sales distribution 73

Leading brands 73

Competitive analysis 74

Strategic growth analysis 76

Adcock Ingram 78

Therapeutic sales distribution 79

Leading brands 80

Competitive analysis 80

Strategic growth analysis 82

Cipla Medpro 83

Therapeutic sales distribution 84

Leading brands 85

Competitive analysis 85

Strategic growth analysis 87

Other leading local companies 89

Leading MNCs 90

Sanofi-Aventis 90

Therapeutic sales distribution 91

Leading brands 91

Competitive analysis 92

Strategic growth analysis 93

Novartis 94

Therapeutic sales distribution 95

Leading brands 95

Competitive analysis 96

Strategic growth analysis 97

Pfizer 98

Therapeutic sales distribution 98

Leading brands 99

Competitive analysis 99

Strategic growth analysis 101

Other leading MNCs 102

Appendix 103

Abbreviations 103

Index 104

List of Figures

Figure 1.1: Channels of healthcare expenditure in South Africa (%), 2008 24

Figure 1.2: South African pharmaceutical market, private-public split, 2009 26

Figure 1.3: Accessibility status of medical schemes in South Africa 27

Figure 1.4: Impact of NHI on the South African market 29

Figure 2.5: Business Insights recommendations concerning key recent events, issues and trends in the South African market 34

Figure 2.6: Clinical trial registrations in South Africa, 2002–09 43

Figure 3.7: Comparison of branded/generic product mix in South Africa and the seven major markets, 2008 59

Figure 3.8: Comparative performance of generic and branded market segments in South Africa, 2007–08 60

Figure 3.9: Comparative sales and volume wise performance of therapy areas in the generics segment, 2008 62

Figure 4.10: Strategic differences between local players and MNCs in South Africa 69

List of Tables

Table 1.1: Socioeconomic indicators of South Africa, 2008 20

Table 1.2: SIPs granted to pharmaceutical projects by the dti, 2007 21

Table 1.3: Demographic profile of South Africa, 2009 (estimates) 22

Table 1.4: DALYs (000s) in South Africa, 2008–14 23

Table 1.5: Consolidated national and provincial health expenditure, 2006–09 25

Table 2.6: South African ARV tender, 2008–10 41

Table 2.7: Single Exit Price criteria 44

Table 3.8: Leading therapy areas in South Africa by sales, 2008 49

Table 3.9: Leading therapy areas in South Africa by volume, 2008 50

Table 3.10: Anti-infectives drug classes, 2008 50

Table 3.11: CVS drug classes, 2008 51

Table 3.12: Pain management drug classes, 2008 52

Table 3.13: Respiratory drug classes, 2008 53

Table 3.14: CNS drug classes, 2008 54

Table 3.15: Therapy area sales forecast, 2009–14 55

Table 3.16: Leading brands in South Africa by sales, 2008 56

Table 3.17: Leading brands in South Africa by volume, 2008 56

Table 3.18: Generic pharmaceutical market in South Africa, 2008 58

Table 3.19: Therapeutic segmentation of South African generics pharmaceutical market, 2008 61

Table 3.20: Leading generics products in South Africa by sales, 2008 63

Table 3.21: Leading generics products in South Africa by volume, 2008 63

Table 4.22: Sales and volume performance of top 20 MNCs and domestic players in South Africa, 2008 68

Table 4.23: Sales performance of top 20 MNCs and domestic players in South Africa in local currency terms, 2008 68

Table 4.24: Therapeutic positioning of leading MNCs and local players, 2008 70

Table 4.25: Top 10 players by sales, 2008 71

Table 4.26: Top 10 players by volumes, 2008 71

Table 4.27: Therapeutic sales distribution of Aspen, 2008 73

Table 4.28: Leading Aspen products by sales, 2008 73

Table 4.29: Therapeutic sales distribution of Adcock Ingram, 2008 79

Table 4.30: Leading Adcock Ingram products by sales, 2008 80

Table 4.31: Therapeutic sales distribution of Cipla Medpro, 2008 84

Table 4.32: Leading Cipla Medpro products by sales, 2008 85

Table 4.33: Emerging South African companies and market positioning, 2008 90

Table 4.34: Therapeutic sales distribution of Sanofi-Aventis, 2008 91

Table 4.35: Leading Sanofi-Aventis products by sales, 2008 91

Table 4.36: Therapeutic sales distribution of Novartis, 2008 95

Table 4.37: Leading Novartis products by sales, 2008 95

Table 4.38: Therapeutic sales distribution of Pfizer, 2008 98

Table 4.39: Leading Pfizer products by sales, 2008 99

Table 4.40: Key franchises added by Pfizer in South Africa through the Wyeth acquisition 102

Table 4.41: Other leading MNCs in South Africa, 2008 102

Companies mentioned Aspen, Adcock Ingram, Cipla Medpro, Sanofi-Aventis, Novartis, Pfizer

To order this report:

Pharmaceutical Industry: South African Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo